Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Free Cash Flow (2016 - 2026)

Mimedx's Free Cash Flow history spans 16 years, with the latest figure at $1.3 million for Q1 2026.

On a quarterly basis, Free Cash Flow fell 73.41% to $1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $69.4 million, a 5.84% increase, with the full-year FY2025 number at $73.0 million, up 11.5% from a year prior.
Free Cash Flow hit $1.3 million in Q1 2026 for Mimedx, down from $24.7 million in the prior quarter.
Over the last five years, Free Cash Flow for MDXG hit a ceiling of $29.1 million in Q3 2025 and a floor of -$10.3 million in Q1 2022.
Historically, Free Cash Flow has averaged $9.1 million across 5 years, with a median of $7.5 million in 2023.
Biggest five-year swings in Free Cash Flow: tumbled 383.5% in 2022 and later surged 2149.67% in 2023.
Tracing MDXG's Free Cash Flow over 5 years: stood at $3.6 million in 2022, then soared by 127.82% to $8.3 million in 2023, then surged by 135.18% to $19.4 million in 2024, then increased by 26.85% to $24.7 million in 2025, then plummeted by 94.69% to $1.3 million in 2026.
Business Quant data shows Free Cash Flow for MDXG at $1.3 million in Q1 2026, $24.7 million in Q4 2025, and $29.1 million in Q3 2025.